Emphysema Market Expected to rise, 2032 | Mereo BioPharma, United Therapeutics, GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Pfizer, Mylan, Novartis, expected to drive market

The Emphysema market growth is driven by factors like increase in the prevalence of Emphysema, investments in research and development, entry of emerging therapies during the study period 2019-2032.
The Emphysema market report [https://www.delveinsight.com/report-store/emphysema-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] also offers comprehensive insights into the Emphysema market size, share, Emphysema epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Emphysema market size growth forward.

Some of the key highlights from the Emphysema Market Insights Report:

*
In early 2024, the FDA expanded the use of Dupixent, developed by Regeneron Pharmaceuticals and Sanofi, to include chronic obstructive pulmonary disease (COPD), which encompasses emphysema. This marks the first targeted biological therapy approved for COPD. Clinical trials demonstrated that Dupixent reduced moderate-to-severe exacerbations by 30% over 52 weeks and improved lung function, with a favorable safety profile.

*
In June 2024, Verona Pharma's Ohtuvayre received FDA approval as the first inhaled therapy with a novel mechanism of action for COPD in over two decades. Ohtuvayre is a dual inhibitor of the phosphodiesterase 3 and 4 enzymes, offering both bronchodilation and anti-inflammatory effects. Phase 3 trials showed significant improvements in lung function and a 40% reduction in exacerbations over 24 weeks in patients with moderate to severe COPD.

*
Olympus Corporation expanded the availability of its Spiration Valve System in March 2022. This minimally invasive device reduces lung hyperinflation in emphysema patients, leading to improved breathing and quality of life.

*
According to DelveInsight, the Emphysema Market is projected to grow at a strong rate from 2023 to 2032, driven by the introduction of new therapies and an increasing number of cases.

*
Several leading pharmaceutical and biotechnology companies, including Mereo BioPharma, United Therapeutics, GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Pfizer, Mylan, and Novartis, are actively engaged in advancing treatments for emphysema.

*
As per DelveInsight analysis, the Emphysema market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Emphysema Market Landscape [https://www.delveinsight.com/sample-request/emphysema-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Emphysema Overview

Emphysema is a chronic lung disease that falls under chronic obstructive pulmonary disease (COPD). It causes damage to the air sacs (alveoli) in the lungs, making it difficult to breathe. Over time, the walls of the alveoli weaken and rupture, reducing the surface area available for oxygen exchange. This leads to shortness of breath, coughing, and wheezing.

Do you know the treatment paradigms for different countries? Download our Emphysema Market Sample Report [https://www.delveinsight.com/report-store/emphysema-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Emphysema Epidemiology Insights

*
Emphysema is a chronic lung condition characterized by the destruction of alveoli, leading to impaired gas exchange. It is a major component of chronic obstructive pulmonary disease (COPD) and is primarily associated with smoking and environmental pollutants. Here's an overview of its epidemiology:

*
The Global Burden of Disease (GBD) Study estimates that COPD affects approximately 10-12% of the world's population over 40 years of age.

Emphysema Epidemiology Segmentation

DelveInsight's Emphysema market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Emphysema historical patient pools and forecasted Emphysema patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Emphysema Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:

*
Emphysema Prevalence

*
Age-Specific Emphysema Prevalence

*
Gender-Specific Emphysema Prevalence

*
Diagnosed and Treatable Cases of Emphysema

Visit for more @ Emphysema Epidemiological Insights [https://www.delveinsight.com/sample-request/emphysema-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Emphysema Market Outlook

The emphysema market is poised for significant growth from 2023 to 2032, driven by the rising prevalence of the disease and the introduction of innovative therapies.

Key Emphysema Market Drivers

*
Increasing Prevalence: Factors such as aging populations and rising smoking rates contribute to a higher incidence of emphysema.

*
Therapeutic Advancements: Ongoing research and development efforts are leading to the introduction of novel treatments, including regenerative therapies and advanced inhalation devices.

*
Awareness and Diagnosis: Improved awareness and diagnostic techniques are facilitating earlier detection and intervention.

Emphysema Key Companies

*
Mereo BioPharma, United Therapeutics, GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Pfizer, Mylan, Novartis, and others

For more information, visit Emphysema Market Analysis, Patient Pool, and Emerging Therapies [https://www.delveinsight.com/report-store/emphysema-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Scope of the Emphysema Market Report:

*
11 Years Forecast

*
7MM Coverage

*
Descriptive overview of Emphysema, causes, signs and symptoms, diagnosis, treatment

*
Comprehensive insight into Emphysema epidemiology in the 7MM

*
Emphysema marketed and emerging therapies

*
Emphysema companies

*
Emphysema market drivers and barriers

Table of Contents:

1 Emphysema Market Key Comprehensive Insights

2 Emphysema Market Report Introduction

3 Competitive Intelligence Analysis for Emphysema

4 Emphysema Market Analysis Overview at a Glance

5 Executive Summary of Emphysema

6 Emphysema Epidemiology and Market Methodology

7 Emphysema Epidemiology and Patient Population

8 Emphysema Patient Journey

9 Emphysema Treatment Algorithm, Emphysema Current Treatment, and Medical Practices

10 Key Endpoints in Emphysema Clinical Trials

11 Emphysema Marketed Therapies

12 Emphysema Emerging Therapies

13 Emphysema: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Emphysema

16 Emphysema Market Key Opinion Leaders Reviews

18 Emphysema Market Drivers

19 Emphysema Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Emphysema Epidemiology 2032

DelveInsight's "Emphysema - Epidemiology Forecast to 2032" report delivers an in-depth understanding of the disease, historical and forecasted Emphysema epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Emphysema Pipeline 2024

"Emphysema Pipeline Insights, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Emphysema market. A detailed picture of the Emphysema pipeline landscape is provided, which includes the disease overview and Emphysema treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=emphysema-market-expected-to-rise-2032-mereo-biopharma-united-therapeutics-glaxosmithkline-astrazeneca-boehringer-ingelheim-glaxosmithkline-pfizer-mylan-novartis-expected-to-drive-market]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.